Multivalent RNA Aptamers That Inhibit CTLA-4 and Enhance Tumor Immunity

Sandra Santulli-Marotto, Smita K. Nair, Chris Rusconi, Bruce Sullenger, Eli Gilboa

Research output: Contribution to journalArticle

124 Citations (Scopus)

Abstract

The potency of cancer immunotherapy can be enhanced by administration of high-avidity ligands specific to receptors expressed on T cells. Antibodies or cytokines are the main agents used in such capacity. Antibody-mediated inhibition of cytotoxic T cell antigen-4 (CTLA-4) function in mice augments antitumor immunity and could serve as an important adjunct in cancer immunotherapy. However, antibody-based therapy used in the setting of chronic diseases such as cancer poses significant cost, manufacturing, and regulatory challenges. Here we describe the development of RNA aptamers that bind CTLA-4 with high affinity and specificity. These aptamers inhibit CTLA-4 function in vitro and enhance tumor immunity in mice. Moreover, assembly of the aptamers into tetrameric forms significantly enhances their bioactivity in vitro and in vivo. These results demonstrate that aptamers can be used to manipulate the immune system for therapeutic applications and that multivalent versions of aptamers may be particularly potent agents in vivo.

Original languageEnglish
Pages (from-to)7483-7489
Number of pages7
JournalCancer Research
Volume63
Issue number21
StatePublished - Nov 1 2003
Externally publishedYes

Fingerprint

Nucleotide Aptamers
Viral Tumor Antigens
Immunity
T-Lymphocytes
Immunotherapy
Antibodies
Neoplasms
Immune System
Chronic Disease
Cytokines
Ligands
Costs and Cost Analysis
Therapeutics
In Vitro Techniques

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Santulli-Marotto, S., Nair, S. K., Rusconi, C., Sullenger, B., & Gilboa, E. (2003). Multivalent RNA Aptamers That Inhibit CTLA-4 and Enhance Tumor Immunity. Cancer Research, 63(21), 7483-7489.

Multivalent RNA Aptamers That Inhibit CTLA-4 and Enhance Tumor Immunity. / Santulli-Marotto, Sandra; Nair, Smita K.; Rusconi, Chris; Sullenger, Bruce; Gilboa, Eli.

In: Cancer Research, Vol. 63, No. 21, 01.11.2003, p. 7483-7489.

Research output: Contribution to journalArticle

Santulli-Marotto, S, Nair, SK, Rusconi, C, Sullenger, B & Gilboa, E 2003, 'Multivalent RNA Aptamers That Inhibit CTLA-4 and Enhance Tumor Immunity', Cancer Research, vol. 63, no. 21, pp. 7483-7489.
Santulli-Marotto S, Nair SK, Rusconi C, Sullenger B, Gilboa E. Multivalent RNA Aptamers That Inhibit CTLA-4 and Enhance Tumor Immunity. Cancer Research. 2003 Nov 1;63(21):7483-7489.
Santulli-Marotto, Sandra ; Nair, Smita K. ; Rusconi, Chris ; Sullenger, Bruce ; Gilboa, Eli. / Multivalent RNA Aptamers That Inhibit CTLA-4 and Enhance Tumor Immunity. In: Cancer Research. 2003 ; Vol. 63, No. 21. pp. 7483-7489.
@article{07af6ba8f509424d866ce7b28b304a54,
title = "Multivalent RNA Aptamers That Inhibit CTLA-4 and Enhance Tumor Immunity",
abstract = "The potency of cancer immunotherapy can be enhanced by administration of high-avidity ligands specific to receptors expressed on T cells. Antibodies or cytokines are the main agents used in such capacity. Antibody-mediated inhibition of cytotoxic T cell antigen-4 (CTLA-4) function in mice augments antitumor immunity and could serve as an important adjunct in cancer immunotherapy. However, antibody-based therapy used in the setting of chronic diseases such as cancer poses significant cost, manufacturing, and regulatory challenges. Here we describe the development of RNA aptamers that bind CTLA-4 with high affinity and specificity. These aptamers inhibit CTLA-4 function in vitro and enhance tumor immunity in mice. Moreover, assembly of the aptamers into tetrameric forms significantly enhances their bioactivity in vitro and in vivo. These results demonstrate that aptamers can be used to manipulate the immune system for therapeutic applications and that multivalent versions of aptamers may be particularly potent agents in vivo.",
author = "Sandra Santulli-Marotto and Nair, {Smita K.} and Chris Rusconi and Bruce Sullenger and Eli Gilboa",
year = "2003",
month = "11",
day = "1",
language = "English",
volume = "63",
pages = "7483--7489",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - Multivalent RNA Aptamers That Inhibit CTLA-4 and Enhance Tumor Immunity

AU - Santulli-Marotto, Sandra

AU - Nair, Smita K.

AU - Rusconi, Chris

AU - Sullenger, Bruce

AU - Gilboa, Eli

PY - 2003/11/1

Y1 - 2003/11/1

N2 - The potency of cancer immunotherapy can be enhanced by administration of high-avidity ligands specific to receptors expressed on T cells. Antibodies or cytokines are the main agents used in such capacity. Antibody-mediated inhibition of cytotoxic T cell antigen-4 (CTLA-4) function in mice augments antitumor immunity and could serve as an important adjunct in cancer immunotherapy. However, antibody-based therapy used in the setting of chronic diseases such as cancer poses significant cost, manufacturing, and regulatory challenges. Here we describe the development of RNA aptamers that bind CTLA-4 with high affinity and specificity. These aptamers inhibit CTLA-4 function in vitro and enhance tumor immunity in mice. Moreover, assembly of the aptamers into tetrameric forms significantly enhances their bioactivity in vitro and in vivo. These results demonstrate that aptamers can be used to manipulate the immune system for therapeutic applications and that multivalent versions of aptamers may be particularly potent agents in vivo.

AB - The potency of cancer immunotherapy can be enhanced by administration of high-avidity ligands specific to receptors expressed on T cells. Antibodies or cytokines are the main agents used in such capacity. Antibody-mediated inhibition of cytotoxic T cell antigen-4 (CTLA-4) function in mice augments antitumor immunity and could serve as an important adjunct in cancer immunotherapy. However, antibody-based therapy used in the setting of chronic diseases such as cancer poses significant cost, manufacturing, and regulatory challenges. Here we describe the development of RNA aptamers that bind CTLA-4 with high affinity and specificity. These aptamers inhibit CTLA-4 function in vitro and enhance tumor immunity in mice. Moreover, assembly of the aptamers into tetrameric forms significantly enhances their bioactivity in vitro and in vivo. These results demonstrate that aptamers can be used to manipulate the immune system for therapeutic applications and that multivalent versions of aptamers may be particularly potent agents in vivo.

UR - http://www.scopus.com/inward/record.url?scp=0242610799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242610799&partnerID=8YFLogxK

M3 - Article

C2 - 14612549

AN - SCOPUS:0242610799

VL - 63

SP - 7483

EP - 7489

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 21

ER -